Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation
The Research Council of Norway is announcing NOK 7 000 000 to Norwegian researchers who want to participate in a European research collaboration on rare diseases.
Projects should focus on a group of rare diseases or a single rare disease if grouping is not justified, providing a rationale for the latter. Consortia are expected to include and engage patient partners and/or patient advocacy organisations (PAOs).
Projects should address at least two of the following:
- Development of novel therapies in a pre-clinical setting.
- Creation and validation of predictive and pharmacodynamic biomarkers.
- Replication of pre-clinical findings to enhance reliability.
- Pre-clinical proof-of-concept studies for therapy readiness.
Please note, certain approaches, including ATMP therapies and clinical trials, are excluded from this call. For guidance about patient’ s involvement please see the call’s website.
Amount of available funding from RCN: € 600 000
Maximum amount of funding per grant: maximum € 300 000 If the Norwegian participant is a partner and maximum € 400.000 if the Norwegian participant has a coordinator role.
Total budget for Norwegian partners in a single project: € 400 000
Amount of total available funding for the call: about 30 million euro
Project duration: 3 years
If the funding recipient is a commercial enterprise, the funding is granted in the form of state aid and is regulated by the state aid rules.
Website: https://erdera.org/funding/